Theratechnologies faces critical disruption in EGRIFTA SV supply following FDA-induced factory shutdown
Theratechnologies Inc., a leading biopharmaceutical company based in Montreal, has announced a potentially significant disruption in the supply of its body fat reduction medication, EGRIFTA ... Read More
Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma's stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to ... Read More
Could vimseltinib be the next big thing in TGCT treatment? FDA says Yes!
The U.S. Food and Drug Administration (FDA) has granted priority review status to Deciphera Pharmaceuticals, Inc.'s New Drug Application (NDA) for vimseltinib, a drug developed ... Read More
FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More